Remove News
article thumbnail

UK MHRA strengthens regulations on fluoroquinolone antibiotics

Pharmaceutical Technology

The UK MHRA has introduced further restrictions on the usage of fluoroquinolone antibiotics, strengthening the previous regulations.

article thumbnail

IRA lawsuits will test US’ ability to regulate social pricing in pharma

Pharmaceutical Technology

As the deadline nears for the government to reveal its proposed prices, pharmaceutical companies are continuing to fight regulation.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Antitrust regulators aim to revamp merger guidelines, signaling threat to health sector deals

Bio Pharma Dive

The news sparked headlines about an attempt by regulators to target big tech, but it could have serious implications for healthcare, too.

article thumbnail

MHRA revamps UK clinical trial regulation with the promise of faster timelines

Pharmaceutical Technology

This week, the Medicines and Healthcare products Regulatory Agency (MHRA) is introducing major changes to clinical trial regulation in the UK with expedited timelines at several stages. The MHRA hopes this new framework “will remove obstacles to innovation” and “streamline the regulation of clinical trials” amongst other things.

article thumbnail

Smaller regulators grasp innovation through international collaboration

Pharmaceutical Technology

At the Swiss Biotech Day Conference, key opinion leaders discussed ways to reduce disparities caused by reduced regulatory capacities.

article thumbnail

In the News: August 2021 Regulatory and Development Updates

Camargo

Each month, Camargo’s “In the News” series highlights important changes and advancements in the regulatory and development space and explores how those changes could impact your program. devices must be regulated as devices, and drugs—if they do not also satisfy the device definition—must be regulated as drugs.”.

article thumbnail

Three regulators accept Bristol Myers’ applications for myeloma therapy

Pharmaceutical Technology

Three regulators in different jurisdictions have accepted Bristol Myers Squibb’s applications for Abecma (idecabtagene vicleucel) for earlier use to treat triple-class exposed relapsed and/or refractory multiple myeloma in adult patients.